OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Khan on the Role of Acalabrutinib in the Current CLL Treatment Paradigm

August 1st 2025

Cyrus M. Khan, MD, discusses how acalabrutinib fits into the current treatment paradigm in chronic lymphocytic leukemia.

Dr Pelz on the Role of Minimally Invasive Surgical Techniques in Lung Cancer

August 1st 2025

Geoffrey B. Pelz, MD, discusses the role of minimally invasive surgical approaches for the treatment of patients with lung cancer.

Dr Braun on Fundamental Immune Defects in Chromophobe RCC

July 31st 2025

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Dr Sinicrope on the Clinical Implications of the ATOMIC Trial for Stage III dMMR CRC

July 31st 2025

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Dr Kuerer on the Safety, Feasibility of Omitting Surgery in Select Patients With HER2+, Triple-Negative Breast Cancer

July 31st 2025

Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.

Dr Riedel on the Role of the Multidisciplinary Team in PEComa Management

July 31st 2025

Richard F. Riedel, MD, discusses the importance of multidisciplinary PEComa management and the role of sarcoma specialists in this disease setting.

Dr Sonpavde on OS Data With Ipilimumab/Nivolumab in Previously Untreated, Advanced Urothelial Carcinoma

July 31st 2025

Guru P. Sonpavde, MD, details overall survival data with ipilimumab/nivolumab vs gemcitabine/platinum in previously untreated, advanced urothelial cancer.

Dr Jacob on the Potential Role for TAR-200 in BCG-Unresponsive, High Risk NMIBC

July 31st 2025

Joseph Jacob, MD, MCR, discusses the potential role of an intravesical gemcitabine delivery system for BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Jamroziak on Daratumumab vs Observation in Multiple Myeloma With MRD Reappearance

July 31st 2025

Krzysztof Jamroziak, PhD, discusses findings from the phase 2 PREDATOR-MRD trial (NCT03697655).

Dr Dietrich on the Efficacy and Safety of Taletrectinib in ROS1+ NSCLC

July 31st 2025

Martin F. Dietrich, MD, PhD, discusses the efficacy and safety profiles of taletrectinib for the management of ROS1-positive non–small cell lung cancer.

Dr Richter on the FDA Approval of Linvoseltamab for R/R Multiple Myeloma

July 31st 2025

Joshua Richter, MD, discusses the FDA approval of linvoseltamab for relapsed or refractory multiple myeloma.

Dr Blanco on the Conditional EU Approval of Mirdametinib for NF1-Associated PNs

July 31st 2025

Ignacio Blanco, MD, PhD, discusses the significance of the European approval of mirdametinib for symptomatic, inoperable plexiform neurofibromas.

Dr Hayne on the Rationale for Evaluating Mitomycin Plus BCG vs BCG Alone in NMIBC

July 31st 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the rationale for evaluating the addition of mitomycin to BCG in non–muscle-invasive bladder cancer.

Dr Salgia on Biomarker-Driven Therapies of Interest for Second-Line SCLC

July 30th 2025

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Dr Kim on the Collaborative, Forward-Thinking Nature of the 2025 BTG in Lung Cancer Meeting

July 30th 2025

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Dr Sen on the Role of Immunotherapy in SCLC

July 30th 2025

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Dr Florez on the Importance of Establishing Consensus Within the Evolving Lung Cancer Treatment Landscape

July 30th 2025

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Dr Lopes on a Cost Analysis of Osimertinib/Chemo vs Amivantamab/Lazertinib in EGFR+ NSCLC

July 30th 2025

Gilberto Lopes, MD, MBA, FAMS, discusses findings from a cost-effectiveness analysis of osimertinib/chemotherapy vs amivantamab/lazertinib in EGFR-mutated NSCLC.

Dr Mascarenhas on Key Considerations for Clinical Trial Enrollment in Myelofibrosis

July 29th 2025

John O. Mascarenhas, MD, discusses important factors to consider when evaluating patients for clinical trial enrollment in myelofibrosis.

Dr Huppert on the Implications of SERENA-6 for Second-Line Treatment Strategies in HR+ Breast Cancer

July 29th 2025

Laura A. Huppert, MD, discusses how the approval of the SERENA-6 regimen could affect second-line treatment decision-making in HR-positive breast cancer.